{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-23-000014","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2023-06-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.200469+00:00","generated_at":"2026-06-14T04:54:16.133032+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Akebia shareholders elect three directors, approve 2023 stock plan at annual meeting","bullets":["Class III directors Adrian Adams, Michael Rogers, LeAnne M. Zumwalt elected for three-year terms.","2023 Stock Incentive Plan approved: 61.2M for, 22.8M against, 508K abstentions.","Non-binding advisory vote on executive compensation passed: 59.7M for, 24.2M against.","Ernst & Young LLP ratified as auditor for FY2023: 116.5M for, 5.2M against."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-23-000014","json":"https://secwatch.observer/filing/0001517022-23-000014.json","markdown":"https://secwatch.observer/filing/0001517022-23-000014.md","text":"https://secwatch.observer/filing/0001517022-23-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702223000014/0001517022-23-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702223000014/akba-20230606.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T04:54:16.133032+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0bff7f286ba5ba20cd30303b880ed5537b20d304","claim":"Akebia Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-12-31 meeting.","evidence_excerpt":"(iii) The proposal to ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 received the following votes: Votes For: 116,535,030 Votes Against: 5,158,525 Abstentions: 1,383,705","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000151702223000014/0001517022-23-000014-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-31"}],"fact_type":"shareholder_vote"},{"claim_id":"53a16c3248ad0e51551b00f6552082a7d0bb503f","claim":"Akebia Therapeutics, Inc. shareholders approved Election of three Class III directors to serve until the 2026 annual meeting.","evidence_excerpt":"The Class III directors elected to the Board, as well as the number of votes for, votes withheld and broker non-votes with respect to each of these individuals, are set forth below: Director Votes For Votes Withheld Broker Non-Votes Adrian Adams 61,064,658 23,449,941 38,562,661 Michael Rogers 64,246,561 20,268,038 38,562,661 LeAnne M. Zumwalt 60,778,528 23,736,071 38,562,661","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000151702223000014/0001517022-23-000014-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"746214a5a33cb4f4a7913dde4e6dad911fe8d904","claim":"Akebia Therapeutics, Inc. shareholders approved Approval of the 2023 Equity Incentive Plan.","evidence_excerpt":"(ii) The proposal to approve the 2023 Plan received the following votes: Votes For: 61,173,115 Votes Against: 22,833,112 Abstentions: 508,372 Broker Non-Votes 38,562,661","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000151702223000014/0001517022-23-000014-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"9df1a7286f68e896d6ed8a904e37a4395a5260e8","claim":"Akebia Therapeutics, Inc. shareholders approved Advisory vote on executive compensation.","evidence_excerpt":"(iii) The advisory vote on the compensation of the Company’s named executive officers received the following votes: Votes For: 59,695,038 Votes Against: 24,230,548 Abstentions: 589,013 Broker Non-Votes 38,562,661","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000151702223000014/0001517022-23-000014-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}